180
Participants
Start Date
January 25, 2022
Primary Completion Date
February 4, 2025
Study Completion Date
February 16, 2026
Ofatumumab
20mg subcutaneous injection
MedStar Health, Washington D.C.
West Virginia University Hospital, Morgantown
Velocity Clinical Research, Raleigh
Shepherd Center, Atlanta
Tallahassee Neurological Clinic, Tallahassee
Emerald Coast Neurology, Pensacola
Univ of Florida College of Medicine, Gainesville
Neurology of Central FL Res Ctr, Altamonte Springs
Neurology Associates PA, Maitland
Orlando Health Clinical Trials, Orlando
First Choice Neurology, Boca Raton
University Of South Florida, Tampa
Sibyl Wray MD Neurology PC, Knoxville
Neurology Diagnostics Inc, Dayton
Medical College of Wisconsin, Milwaukee
Ochsner Cancer Institute, New Orleans
Multiple Sclerosis Center of Excellence of OMRF, Oklahoma City
UT Health Science Center, Houston
Lonestar Neurology of San Antonio, San Antonio
UC Health Neuroscience Ctr, Aurora
Barrow Neurological Clinics at St Josephs Hospital and MC, Phoenix
Arizona Neuroscience Research LLC, Phoenix
MD First Research, Chandler
Renown Institute for Neurosciences, Reno
Keck School of Medicine, Los Angeles
Regina Berkovich MD PhD Inc, West Hollywood
Evergreen Health Multiple Sclerosis Center, Kirkland
MultiCare Neuroscience Center of Washington, Tacoma
Lundquist Inst BioMed at Harbor, Torrance
University of Massachusetts Medical School, Worcester
Henry Ford Hospital, Detroit
Neuroscience Institute at Hackensack, Hackensack
University of New Mexico, Albuquerque
Thomas Jefferson University Hospital, Philadelphia
Univ of Texas Southwest Med Center, Dallas
Caribbean Center for Clinical Research, Inc, Guaynabo
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY